No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 9 of the 30 quarters in the window, leaving 21 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 7.3x · 10Y median 56.4x · 4th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 31
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T17:51:27.745Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for 4D Molecular Therapeutics, Inc. (FDMT) stock was $12.77 as of Oct 6, 2026, 1:50 PM EDT, down 1.20% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +50.8% · 3-year avg +1.6%/yr · 5-year avg -13.1%/yr
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology.
Biotechnology · EmeryVille, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Nov 10, 2026
35 days away
EPS Estimate
-1.04
Revenue Est.
$3.46M
Last Quarter Results
EPS
$-1.04
vs Estimate
$-1.02
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1FDMT | $667.31M | $12.77 | -1.20% | +50.81% | -13.08% | N/A | N/A |
| 2MDXG | $667.67M | $4.58 | +0.67% | -36.75% | -4.94% | -6.46% | vs FDMT |
| 3ANNX | $666.02M | $4.07 | -3.21% | +31.49% | -26.29% | N/A | vs FDMT |
| 4HELP | $671.91M | $10.84 | -5.08% | N/A | N/A | N/A | vs FDMT |
| 5AVBP | $674.71M | $14.49 | -49.10% | +43.20% | N/A | N/A | vs FDMT |
| 6STLN | $657.89M | $6.58 | +4.44% | N/A | N/A | N/A | vs FDMT |
forward FY estimate
N/A
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$3.78M
vs Estimate
$3.62M
Consensus Rating
Based on 11 analysts
Average Price Target
$28.18
+120.8% upside
Low
$18.00
Current
$12.77
High
$37.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.08 | $-1.05 | $-0.99 | 7 |
| Quarter ending Dec 2026 | $-1.12 | $-1.04 | $-1.00 | 7 |
| Quarter ending Mar 2027 | $-1.11 | $-1.09 | $-1.08 | 2 |
| Quarter ending Jun 2027 | $-1.13 | $-1.11 | $-1.09 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-4.28 | $-4.14 | $-3.94 | 7 |
| FY 2027 | $-4.34 | $-4.09 | $-3.50 | 7 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $3.18M | $3.46M | $3.75M | 5 |
| Quarter ending Dec 2026 | $4.28M | $4.33M | $4.38M | 5 |
| Quarter ending Mar 2027 | $3.96M | $4.00M | $4.04M | 4 |
| Quarter ending Jun 2027 | $3.96M | $4.00M | $4.04M | 4 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $7.18M | $12.95M | $15.77M | 8 |
| FY 2027 | $16.25M | $18.34M | $20.43M | 6 |
